Camp4 Therapeutics Corp美股招股说明书(2025-12-18版)

5,000,000 Shares of Common Stock We are offering 5,000,000 shares of our common stock pursuant to this prospectus supplement and accompanying prospectus. Our common stock is listed on The Nasdaq Global Market under the symbol “CAMP.” On December 17, 2025, the last reportedsale price per share of our common stock was $7.13. An investment in our common stock involves significant risks. You should carefully consider the risks and uncertaintiesdescribed under the heading “Risk Factors” beginning on pageS-10of this prospectus supplement and in the accompanyingprospectus, as well as those contained in the other documents that are incorporated by reference into this prospectussupplement, the accompanying prospectus and any related free writing prospectus. You should carefully read this entireprospectus supplement and the accompanying prospectus, including any information incorporated by reference hereto andthereto, before deciding whether to purchase shares of our common stock. Offering priceUnderwriting discounts and commissionsProceeds to CAMP4 Therapeutics Corporation, before expenses(1) (1)See “Underwriting” beginning on pageS-21of this prospectus supplement for additional information regarding underwriting compensation. Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapprovedof these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus.Any representation to the contrary is a criminal offense. The shares of common stock will be ready for delivery against payment therefor on or about December 19, 2025. Leerink Partners Prospectus Supplement dated December 18, 2025 TABLE OF CONTENTS PROSPECTUS SUPPLEMENT ABOUT THIS PROSPECTUS SUPPLEMENTSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATAPROSPECTUS SUPPLEMENT SUMMARYTHE OFFERINGRISK FACTORSUSE OF PROCEEDSDILUTIONMATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR INVESTORS IN COMMON STOCKUNDERWRITINGLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE PROSPECTUS ABOUT THIS PROSPECTUSABOUT THE COMPANYRISK FACTORSSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATAUSE OF PROCEEDSPLAN OF DISTRIBUTIONDESCRIPTION OF COMMON STOCKDESCRIPTION OF PREFERRED STOCKDESCRIPTION OF WARRANTSDESCRIPTION OF DEBT SECURITIESWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF CERTAIN DOCUMENTS BY REFERENCELEGAL MATTERSEXPERTS ABOUT THIS PROSPECTUS SUPPLEMENT This document is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”) utilizinga “shelf” registration process and consists of two parts. The first part is this prospectus supplement, which describes the specific termsof this common stock offering and also adds to and updates information contained in the accompanying prospectus and the documentsincorporated by reference herein. The second part, the accompanying prospectus, provides more general information. Generally, whenwe refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between theinformation contained in this prospectus supplement and the information contained in the accompanying prospectus or any documentincorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in thisprospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another documenthaving a later date—for example, a document incorporated by reference in the accompanying prospectus—the statement in thedocument having the later date modifies or supersedes the earlier statement. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to anydocument that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in somecases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of ouraffairs. Neither we nor the underwriter has authorized anyone to provide any information other than that contained or incorporated byreference into this prospectus supplement, the accompanying prospectus or in any free writing prospectus prepared by or on behalf ofus or to which we have referred you. We and the underwriter take no responsibility for, and can provide no assurance as to thereliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus do notconstitute an offer to sell, or a soli